GrønlandsBANKEN A/S undersøger muligheden for at udstede supplerende kapital
Som del af den løbende proces med at optimere bankens kapitalstruktur, har GrønlandsBANKEN A/S besluttet at undersøge muligheden for udstedelse af supplerende kapital (Tier 2).
I tilfælde af en tilfredsstillende interesse i markedet forventes udstedelserne at finde sted inden udgangen af anden kvartal 2023.
Nykredit Bank A/S er udpeget som arrangør af udstedelsen.
Eventuelle henvendelser kan rettes til:
GrønlandsBANKEN
Martin Kviesgaard
Bankdirektør
Direkte telefon: +299 34 78 02
mbk@banken.gl
Vedhæftet fil
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Wolters Kluwer 2024 Annual General Meeting of Shareholders adopts all resolutions8.5.2024 13:08:18 CEST | Press release
PRESS RELEASE Wolters Kluwer 2024 Annual General Meeting of Shareholders adopts all resolutions Shareholders approve a total dividend of €2.08 per ordinary share Alphen aan den Rijn – May 8, 2024 – Wolters Kluwer (Euronext: WKL), a global leader of professional information, software solutions, and services, announces that all resolutions were adopted as proposed at today’s Annual General Meeting of Shareholders (AGM). Composition Supervisory Board David Sides has been appointed as a member of the Supervisory Board of Wolters Kluwer for a term of four years. Mr. Sides is President and CEO of NextGen Healthcare, a leading provider of innovative technology solutions focused on ambulatory care. Sophie Vandebroek has been reappointed as a member of the Supervisory Board for a second term of four years, and Jack de Kreij has been reappointed for a two-year term. Jeanette Horan, whose second four-year term expired after the AGM, regretfully has informed Wolters Kluwer that she is not availabl
Brookfield Asset Management Announces Strong First Quarter Results8.5.2024 12:45:00 CEST | Press release
Insurance Flows and Castlelake Add $75 Billion of AUM Since Quarter End $106 Billion of Dry Powder Available to Invest BROOKFIELD, NEWS, May 08, 2024 (GLOBE NEWSWIRE) -- Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) today announced financial results for the quarter ended March 31, 2024. Connor Teskey, President of Brookfield Asset Management stated, “We are off to a strong start in 2024 and are seeing accelerating momentum across our business as transaction activity picks up. We raised $20 billion of capital during the first quarter ($10 billion since our last earnings release), and with more than $100 billion of dry powder to invest, both the diversity of our business mix and our global footprint mean that we remain very well-positioned to capture investment opportunities.” He continued, “We recently completed a $50 billion asset management mandate with American Equity Investment Life (AEL) and announced our intention to acquire a majority stake in Castlelake, a leader in ass
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights8.5.2024 12:45:00 CEST | Press release
COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD)Michael Gold to join Compass as Head of R&DCompass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care Cash position of $262.9 million at March 31, 2024 Conference call May 8 at 8:00 am ET (1:00 pm UK) LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2024 and provided an update on recent business progress. Kabir Nath, Chief Executive Officer, said, “We were pleased to see the positive results from the phase 2 PTSD study, a condition with significant unmet nee
Temenos Multifonds extends partnership with Citi Securities Services to consolidate global funds services on Multifonds SaaS8.5.2024 12:36:51 CEST | Press release
Move to Multifonds SaaS enables Citi Securities Services to manage its global business efficiently on a single platform GENEVA, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Today, Temenos (SIX: TEMN) announced that Multifonds has extended its relationship with Citi Securities Services to consolidate its current regional fund accounting operation into a global operating model on Temenos Multifonds delivered as SaaS. Citi Securities Services provides end-to-end services for asset managers globally, using Multifonds as part of its existing investment accounting platform. The move to a global operating model for its global fund services business and from an on-premise system to Multifonds SaaS enables Citi Securities Services to manage its business across multiple geographies and asset classes efficiently on a single platform which includes delivering fund accounting services earlier in the day across all time zones. Citi's Global Head of Securities Services, Okan Pekin, commented: “The m
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder8.5.2024 12:30:00 CEST | Press release
Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 point reduction at week 12), with change from baseline in mean SDS total score (14.4 point reduction at week 12)81.8% response (reduction of ≥ 15 points in CAPS-5 score), 63.6% remission (total CAPS-5 ≤ 20) rates at week 4 with 77.3% response and 54.5% remission at week 12 Measures of symptom scores relative to baseline improved following a single 25mg dose administered with psychological support (n=22) LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced top-line results from an open-label phase 2 study evaluating the safety and tolerability of investigational COMP360 psilocybin treatment in 22 patients with post-traumatic stress dis